Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Anal Canal Carcinoma × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 242 Carcinoma, Non-Small-Cell Lung 170 Prostatic Neoplasms 155 Stomach Neoplasms 93 Lung Neoplasms 83 Squamous Cell Carcinoma of Head and Neck 64 Head and Neck Neoplasms 57 Esophageal Neoplasms 54 Neoplasms 41 Nasopharyngeal Carcinoma 30 Neoplasm Metastasis 29 Pancreatic Neoplasms 27 Sarcoma 25 Urinary Bladder Neoplasms 24 Ovarian Neoplasms 24 Triple Negative Breast Neoplasms 20 Adenocarcinoma 18 Carcinoma, Squamous Cell 17 Adenocarcinoma Of Esophagus 17 Esophageal Squamous Cell Carcinoma 15 Carcinoma, Transitional Cell 13 Salivary Gland Neoplasms 12 Carcinoma, Ovarian Epithelial 12 Unspecified Adult Solid Tumor, Protocol Specific 11 Breast Neoplasms, Male 11 Adenocarcinoma of Lung 10 Uterine Cervical Neoplasms 9 Small Cell Lung Carcinoma 9 Melanoma 8 Leiomyosarcoma 8

Interventions

Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiation 2 Fluorouracil 2 Cisplatin 2 toripalimab 1 pembrolizumab 1 atezolizumab 1 Vaccines 1 Radiosurgery 1 Neoadjuvant Therapy 1 Mitomycins 1 Magnetic Resonance Spectroscopy 1 Immune Checkpoint Inhibitors 1 Docetaxel 1 Chemoradiotherapy 1 Capecitabine 1 Brachytherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02402842 2022-05-16

Epitopes-HPV02

Centre Hospitalier Universitaire de Besancon

Phase 2 Completed

Gastrointestinal

Anal Canal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡